Literature DB >> 6785887

Disseminated gonococcal infection (DGI) and gonococcal arthritis (GCA): II. Clinical manifestations, diagnosis, complications, treatment, and prevention.

A T Masi, B I Eisenstein.   

Abstract

This is the second part of an integrated review of disseminated gonococcal infection (DGI) and gonococcal arthritis (GCA). It covers clinical manifestations, spectrum of GCA, diagnosis and treatment. These disorders are important since DGI may be the most frequent form of acute arthritis in sexually active younger females, and other selected groups. Although the spectrum of disease is varied, it may be classified into stages and clinical subgroups. N. gonorrhoeae strains causing DGI in the U.S. have been highly sensitive to penicillin. Such findings require revision in beliefs that high-dose intravenous penicillin is needed for effective initial therapy of GCA. Recommended treatment protocols for localized gonorrhea and DGI are reviewed as well as the occurrence and implications for treatment of penicillinase-producing N. gonorrhoeae (PPNG) infection in the U.S.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6785887     DOI: 10.1016/s0049-0172(81)80002-9

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  12 in total

Review 1.  Neisseria gonorrhoeae host adaptation and pathogenesis.

Authors:  Sarah Jane Quillin; H Steven Seifert
Journal:  Nat Rev Microbiol       Date:  2018-02-12       Impact factor: 60.633

2.  Disseminated gonococcal infection in an elderly patient.

Authors:  I Rúa Figueroa; E Loza Cortina; S González Suárez; C E Arruabarrena; J L Peña Sagredo
Journal:  Ann Rheum Dis       Date:  1993-01       Impact factor: 19.103

3.  Comparison of isolates of Neisseria gonorrhoeae causing meningitis and report of gonococcal meningitis in a patient with C8 deficiency.

Authors:  C Del Rio; D S Stephens; J S Knapp; R J Rice; W O Schalla
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

4.  A lytic transglycosylase of Neisseria gonorrhoeae is involved in peptidoglycan-derived cytotoxin production.

Authors:  Karen A Cloud; Joseph P Dillard
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

5.  Structure-Activity Relationship Studies of Acetazolamide-Based Carbonic Anhydrase Inhibitors with Activity against Neisseria gonorrhoeae.

Authors:  Chad S Hewitt; Nader S Abutaleb; Ahmed E M Elhassanny; Alessio Nocentini; Xufeng Cao; Devon P Amos; Molly S Youse; Katrina J Holly; Anil Kumar Marapaka; Weiwei An; Jatinder Kaur; Aaron D Krabill; Ahmed Elkashif; Yehia Elgammal; Amanda L Graboski; Claudiu T Supuran; Mohamed N Seleem; Daniel P Flaherty
Journal:  ACS Infect Dis       Date:  2021-03-25       Impact factor: 5.084

6.  In vivo efficacy of acetazolamide in a mouse model of Neisseria gonorrhoeae infection.

Authors:  Nader S Abutaleb; Ahmed E M Elhassanny; Mohamed N Seleem
Journal:  Microb Pathog       Date:  2022-02-19       Impact factor: 3.738

7.  Gonococcal arthritis: case series of 58 hospital cases.

Authors:  Aurore Moussiegt; Claire François; Olivier Belmonte; Julien Jaubert; Nicolas Traversier; Sandrine Picot; Françoise Josse; Xavier Guillot; Patrice Poubeau; Marie-Pierre Moiton; Antoine Bertolotti; Loïc Raffray
Journal:  Clin Rheumatol       Date:  2022-05-20       Impact factor: 3.650

Review 8.  Chronic gonococcal arthritis with C5 deficiency presenting with brief flare-ups: case study and literature review.

Authors:  B Davido; A Dinh; A Lagrange; G Mellon; P de Truchis; C Perronne; A C Cremieux
Journal:  Clin Rheumatol       Date:  2014-04-29       Impact factor: 2.980

9.  Cutaneous vasculitis as the sole manifestation of disseminated gonococcal infection: case report.

Authors:  M Mastrolonardo; F Loconsole; A Conte; F Rantuccio
Journal:  Genitourin Med       Date:  1994-04

10.  Rheumatological manifestations of infective endocarditis.

Authors:  P Thomas; J Allal; D Bontoux; F Rossi; J Y Poupet; J P Petitalot; B Becq-Giraudon
Journal:  Ann Rheum Dis       Date:  1984-10       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.